The American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters Release New AD Guidelines
New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. The Joint Task Force is a partnership between the American College of Allergy, Asthma, and Immunology (ACAAI) and the American Academy of Allergy, Asthma […]
Study: Air Pollution Triggers Summer AD Surge
Air pollution may contribute to the development or worsening of skin conditions such as atopic dermatitis and eczema, according to researchers out of Massachusetts General Hospital (MGH). The work, which is published in Dermatology and Therapy, points to the need to improve air quality to lower the burden of skin disease, especially for vulnerable communities. For the […]
FDA OKs Can-Fite’s Plan to Study Piclidenoson in Kids With Psoriasis
The U.S. Food and Drug Administration (FDA) has green lighted Can-Fite’s plan to include children with psoriasis in studies of Piclidenoson, a small molecule, adenosine A3 receptor (A3AR) agonist. The Pediatric Study Plan would allow enrollment of children with psoriasis to Can-Fite’s upcoming Phase 3 pivotal clinical psoriasis studies, aiming at registration of Piclidenoson with both the FDA […]
Unpacking the Gut-skin Connection in AD
The gut-skin connection is a key factor in atopic dermatitis (AD), according to a new review study in the International Journal of Molecular Sciences. “Besides being responsible for 70% of immune system regularization, for maintaining skin barrier integrity and the structure of the gastrointestinal tract, and for controlling nutrient absorption and energy balance, the gut […]